NFE2L2 and ovarian carcinoma: Moreover, cotreatment with an NRF2 inhibitor (bexarotene) can further repress the EGFR signalling pathway and might sensitize the ovarian cancer cells to the killing effects of lapatinib and/or erlotinib.